Drug Detail

Drug Name Doxorubicin
Trade Name Adriamycin
Synonyms Adria|ADR
Drug Descriptions

Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).

DrugClasses Chemotherapy - Anthracycline 11 TOPO2 inhibitor 4

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
MEDI4736 + R2-CHOP
CHOP + Rituximab
Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others
AC + exemestane + Paclitaxel + Pertuzumab + Trastuzumab
Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib
Doxorubicin + Etoposide + Fludarabine + Vincristine
Carboplatin + Doxorubicin
Doxorubicin + Gemcitabine + Pembrolizumab + Vinorelbine Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).
ABT-737 + Doxorubicin
Rituximab + Fludarabine + EPOCH
Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110
Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab
PLX4720 + Doxorubicin
Doxorubicin + RG7386
CHOP + Obinutuzumab + RO7082859
CPI-0610 + Doxorubicin
Carboplatin + Doxorubicin + Etoposide
Bortezomib + Dasatinib + Dexamethasone + Doxorubicin + Palbociclib
Obinutuzumab + CHOP
Doxorubicin + Olaratumab
Cyclophosphamide + Doxorubicin + Rituximab + Polatuzumab Vedotin + Prednisone
Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide
Doxorubicin + GSK2830371
Doxorubicin + Ifosfamide + Mesna + Olaratumab
Avastin + Doxorubicin + Docetaxel
Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab
CHOP + Rituximab + TAK-659
Dinaciclib + Doxorubicin
AB928 + Doxorubicin
Doxorubicin + Sirolimus
MLN4924 + VXLD
Dacarbazine + Doxorubicin + Vinblastine + Nivolumab
Fludarabine + EPOCH
Doxorubicin + NU7441
CHOP + Rituximab + RO7082859
Vincristine + Dexamethasone + Pegaspargase + Doxorubicin
Alvocidib + Doxorubicin
Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab
Carboplatin + Doxorubicin + Irinotecan + Vincristine
CHOP + Nivolumab + Rituximab
Cisplatin + Doxorubicin + Cyclophosphamide
Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide
Doxorubicin + Ribociclib
R-da-EPOCH
Doxorubicin + SLCB050
Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide
Doxorubicin + Sorafenib
Iniparib + doxorubicin + carboplatin
EPOCH
APX005M + Doxorubicin + Olaratumab
Doxorubicin + Flourouracil + Cyclophosphamide
Dalantercept + Doxorubicin
Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine
Pazopanib + Doxorubicin + Ifosfamide
Alectinib + Doxorubicin
Cisplatin + Doxorubicin + Sorafenib
Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine
Dexamethasone + Doxorubicin + Vincristine
Doxorubicin + Seliciclib
Nivolumab + REPOCH
Atezolizumab + Cyclophosphamide + Doxorubicin
R-EPOCH
Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine
ABVD (Bleomycin + Dacarbazine + Doxorubicin + Vinblastine) + Pembrolizumab
Doxorubicin + Prexasertib
Cyclophosphamide + Doxorubicin + Etoposide + Vincristine
Doxorubicin + Cyclophosphamide
Doxorubicin + Ifosfamide
AZD3463 + Doxorubicin
Doxorubicin + Vorinostat
Cytarabine + Doxorubicin + Methotrexate + Vincristine
Doxorubicin + Nilotinib
Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel
Cyclophosphamide + Doxorubicin + Elenagen
R-CHP
Bleomycin + Dacarbazine + Doxorubicin + Vinblastine
I-CBP112 + Doxorubicin
Doxorubicin + Trabectedin
AC + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab
Doxorubicin
Doxorubicin + Pembrolizumab
EPOCH + Nivolumab
Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab
Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine
Docetaxel + Doxorubicin + Cyclophosphamide
Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide
Doxorubicin + Bevacizumab
Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab
Cisplatin + Doxorubicin + Fluorouracil + Vincristine
Bevacizumab + Doxorubicin + Everolimus
Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine
GANT61 + Doxorubicin
AC + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab
Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab
Docetaxel + Doxorubicin + Pembrolizumab
Cyclophosphamide + Doxorubicin + Prednisone
Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone
MEDI5117 + Doxorubucin
Selinexor + Doxorubicin
COPDAC-28 + Pembrolizumab
SPI-001 + Doxorubicin
R-MACLO/IVAM
Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin
AMG 232 + Doxorubicin
Bevacizumab + Doxorubicin + Temsirolimus
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine
Doxorubicin + FX1
Cambinol + Doxorubicin
BTCT4465A + CHOP
Doxorubicin + Olaratumab + Trabectidin
Cisplatin + Doxorubicin
Paclitaxel + Doxorubicin + Cyclophosphamide
Doxorubicin + Tozasertib
Cyclophosphamide + Doxorubicin + Vincristine
Cyclophosphamide + Doxorubicin + Pertuzumab + Tamoxifen + Trastuzumab
MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone
AC + Anastrozole + Paclitaxel + Pertuzumab + Trastuzumab
Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide
APR-246 + Carboplatin + Doxorubicin
Cyclophosphamide + Doxorubicin + Eribulin
Doxorubicin + Lurbinectedin
Dexamethasone + Doxorubicin
ACY-957 + Doxorubicin
Venetoclax + DA-EPOCH-R
Cyclophosphamide + Doxorubicin + Pembrolizumab
MK-1775 + Doxorubicin
Doxorubicin + Safingol
BTCT4465A + Cyclophosphamide + Doxorubicin + Polatuzumab Vedotin + Prednisone BTCT4465A is a bispecific antibody targeting CD20 and CD3, which results in killing of CD20-positive tumor cells (PMID: 25972002)
Doxorubicin + Paclitaxel
Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab
Doxorubicin + Etoposide + Vincristine
Doxorubicin + NU6027
Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, urothelial carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).
Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide